Loading
NASDAQHealthcareBiotechnology
Latest quote
$11.29
−$0.61 · -5.13%
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Previous close
$11.29
−$0.61 · -5.13%
Regular session · ET · Market data may be delayed.
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Day range
Current $11.29
52-week range
Current $11.29
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
54
Fair Value
Sentiment
41
Mixed
Risk
53
Elevated Risk
Momentum
60
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Day range
Current $11.29
52-week range
Current $11.29
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (AUD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.21B AUD | 783.21M AUD | 502.55M AUD | 160.1M AUD | 7.6M AUD |
| Cost of goods sold | 565.2M AUD | 273.53M AUD | 188.16M AUD | 65.17M AUD | 38.68M AUD |
| Gross profit | 640.23M AUD | 509.68M AUD | 314.39M AUD | 94.93M AUD | 5.05M AUD |
| Research and development | 256.82M AUD | 121.03M AUD | 128.84M AUD | 57.86M AUD | 34.14M AUD |
| Selling, general, and administrative | 356.77M AUD | 207.13M AUD | 134.16M AUD | 87.1M AUD | 46.99M AUD |
| Operating expenses | 613.59M AUD | 427.55M AUD | 263.27M AUD | 186.86M AUD | 53.3M AUD |
| Interest income | 8.74M AUD | 10.86M AUD | 671K AUD | 1K AUD | — |
| Interest expense | 55.06M AUD | 21.46M AUD | 8.94M AUD | 406K AUD | 195.68K AUD |
| Depreciation and amortization | 32.67M AUD | 5.69M AUD | 6.74M AUD | 5.38M AUD | 5.17M AUD |
| Operating income | 26.64M AUD | 82.13M AUD | 15.84M AUD | −91.93M AUD | −81.25M AUD |
| Net income | −10.69M AUD | 49.92M AUD | 5.21M AUD | −104.08M AUD | −80.51M AUD |
Company facts updated Sep 12, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$18.00
59.43% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Schwab International Equity ETFSCHF19.17M0.03%69.45B USD0.03%$28.19+1.11%
State Street SPDR Portfolio Developed World ex-US ETFSPDW10.86M0.03%42.01B USD0.03%$51.56+1.12%
Schwab Fundamental International Small Company Index ETFFNDC4.85M0.15%3.16B USD0.39%$51.09+0.95%
State Street SPDR Portfolio Europe ETFSPEU370.61K0.05%722.64M USD0.07%$55.65+0.55%
State Street SPDR MSCI EAFE StrategicFactors ETFQEFA262.3K0.03%1.03B USD0.30%$99.9761+0.56%
State Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAX224.19K0.04%504.91M USD0.20%$54.875+0.58%
ActivePassive International Equity ETFAPIE132.04K0.01%953.79M USD0.45%$39.20+0.89%
Applied Finance IVS International Large ETFIVSI33.3K0.35%6.04M USD0.65%$29.50+0.85%Schwab International Equity ETFSCHFState Street SPDR Portfolio Developed World ex-US ETFSPDWSchwab Fundamental International Small Company Index ETFFNDCState Street SPDR Portfolio Europe ETFSPEUState Street SPDR MSCI EAFE StrategicFactors ETFQEFAState Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAXActivePassive International Equity ETFAPIEApplied Finance IVS International Large ETFIVSIAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
